Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Articles

Vol. 2 No. 4 (2011): October-December 2011

Modified 9H-fluorene-9-carboxamides as MTP-inhibitors

DOI
https://doi.org/10.37285/ijddd.2.4.1
Submitted
December 9, 2024
Published
2024-12-09

Abstract

Introduction
Metabolic disorder is a cluster of disorder of metabolism like hyperglycemia, dyslipidemia and obesity. Any of these alone or in combination can lead to high risk for the development of high levels of cholesterol, triglyceride and insulin resistance.

References

  1. [1] Reaven, G.M.; Chen, Y.D.; Jeppesen, J; Maheux, P; Krauss, R. M.; J Clin. Invest 1993, 92, 141.
  2. [2] Taskinen, M. R.; Tchernof, A.; Lamarche, B.; Prud, H. D.; Nadeau, A,; Moorjani, S.; Labrie, F.; Lupien, P. J.; Curr. Opin. Lipidol. 1995, 6, 153.
  3. [3] Kugiyama, K.; Doi, H.; Takazoe, K.; Kawano, H.; Soejima, H.; Mizuno, Y.; Tsunoda, R.; Sakamoto, T.; Nakano, T.; Nakajima, K.; Ogawa, H.;, Sugiyama, S.;, Yoshimura, M.; Yasue, H.;. Circulation 1999;99:2858-60.
  4. [4] Mero, N.; Malmström, R.; Steiner, G.; Taskinen, M. R.; Syvänne, M.; e. Atherosclerosis 2000, 150, 167.
  5. [5] Karpe, F.; Steiner, G.;, Uffelman, K.; Olivercrona, T.;, Hamsten, A.;. Atherosclerosis 1994,; 106, 83..
  6. [6] 1. Wetterau, J. R.; Gregg, R. E.; Harrity, T. W.; Arbeeny, C.; Cap, M.; Connolly, F.; Chu, C.-H.; George, R. J.; Gordon, D. A.; Jamil, H.; Jolibois, K. G.; Kunselman, L. K.; Lan, S.-J.; Maccagnan, T. J.; Ricci, B.; Yan, M.; Young, D.; Chen, Y.; Fryszman, O. M.; Logan, J. V. H.; Musial, C. L.; Poss, M. A.; Robl, J. A.; Simpkins, L. M.; Slusarchyk, W. A.; Sulsky, R.; Taunk, P.; Magnin, D. R.; Tino, J. A.;Lawrence, R. M.; Dickson, J. K., Jr.; Biller, S. A. Science 1998, 282, 751.
  7. [7] Gleeson, A.; Anderton, K.; Owens, D.; Bennett, A.; Collins, P.; Johnson, A.; White, D.; Tomkin, G. H. Diabetologia 1999, 42,:944.
  8. [8] Phillips, C.; Bennett, A.; Anderton, K.; Owens, D.; Collins, P.; White, D.; Tomkin, G. H.; Metabolism 2002, 51,847
  9. [9] Phillips, C.; Owens, D.; Collins, P.; Tomkin, G. H. Atherosclerosis 2002, 160, 355
  10. [10] (a) Wetterau, J. R.; and Zilversmit, D.B.; Biochim. Biophys.Acta 875, 610 (1986). (b). Wetterau, J. R.; Combs, S. N. Spinner, S.N.; Joiner, B.J, J. Biol. Chem. 1990, 265, 9800,
  11. [11] Williams, S. J.; Best, J. D. Expert Opin. Ther. Patents 2003, 13, 479
  12. [12] (a) Chang, G.; Ruggeri, R. B.; Harwood, H. J. Jr.. Curr. Opin. Drug Discov. Devel.2002, 5, 562
  13. [13] Wetterau, J. R.; Gregg, R. E.; Harrity, T. W.; Arbeeny, C.; Cap, M.; Connolly,F.; Chu, C.-H.; George, R. J.; Gordon, D. A.; Jamil, H.; Jolibois, K. G.; Kunselman,L. K.; Lan, S.-J.; Maccagnan, T. J.; Ricci, B.; Yan, M.; Young, D.; Chen, Y.; Fryszman, O.M.; Logan, V. H.;Musial, C. L.; Poss, M. A.; Robl, J. A.; Simpkins, L. M.;Slusarchyk, W. A.; Sulsky, R.; Taunk, P.; Magnin, D. R.; Tino, J. A.; Lawrence, R.M., ; Dickson, J. K., Jr.; Biller, S. A. Science 1998, 282, 751.
  14. [14] Frederick, F.; Samaha1, J.M.;, LeAnne, T. B.;.;,William, J S.;, Daniel, J. R..; Nature clinical practice cardiovascular medicine
  15. [15] Wetterau,, J. R..; and Zilversmit, D. B.;.1984. J.Biol. Chem 1984, 259, 10863,
  16. [16] Robertson, R.P.;, Gavareski, D.J.;, Henderson, J.D.;, Porte, D. Bierman, E.L.;. ,J Clin Invest. 1973, 52,7,1620.